Sažetak
Uvod. Primarna mijelofibroza je klonsko mijeloproliferativno oboljenje koje se najčeščće javlja u šestoj deceniji života, a vrlo retko kod mladih osoba. Prikaz bolesnika. Prikazana je 28-godišnja bolesnica sa primarnom mijelofibrozom, koja je imala normalnu trudnoću i porođaj u četrdesetoj nedelji trudnoće bez komplikacija. Tokom cele trudnoće bolesnica je lečena interferonom alfa i niskim dozama aspirina, a nedelju dana pre i 6 nedelja nakon porođaja primenjen je i niskomolekularni heparin u profilaktičkim dozama. Bolesnica nije imala komplikacije tokom trudnoće i rodila je zdravu bebu normalne težine. Zaključak. Odluka o strategiji lečenja trudnica sa prisutnim hematološkim malignitetima treba da bude doneta posebno za svaku bolesnicu.
Ključne reči
||mijeloproliferativni poremećaji
primary myelofibrosis||
||primarna mijelofibroza
pregnancy||
||trudnoća
interferon-alpha||
||interferon-alfa
treatment outcome||
||lečenje
ishod
Reference
Swerdlow SH, Campo E, Harris NL, Jaffe, ES, Pileri, SA, Stein, H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification and management. Am J Hematol 2011; 86(12): 1017−26.
Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev 2008; 22(5): 235−45.
McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hema-tol Oncol 1997; 15(4): 173−89.
Taylor UB, Bardeguez AD, Iglesias N, Gascon P. Idiopathic mye-lofibrosis in pregnancy: a case report and review of the litera-ture. Am J Obstet Gynecol 1992; 167(1): 38−9.
Gotić M, Cvetković M, Bozanović T, Cemerikić V. Successful treatment of primary myelofibrosis with thrombocytosis dur-ing pregnancy with alfa-interferon. Srp Arh Celok Lek 2001; 129(11−12): 304−8.
Tulpule S, Bewley S, Robinson SE, Radia D, Nelson-Piercy C, Harrison CN. The management and outcome of four pregnancies in women with idiopathic myelofibrosis. Br J Haemat 2008; 142(3): 480−2.
Randi ML, Rossi C, Fabris F, Girolami A. Essential thrombo-cythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 pa-tients. Clin Appl Thromb Hemost 2000; 6(1): 31−5.
Bai Y, Zhang C, Wang J, Liang M, Zhang X. Clinical analysis of eleven patients with chronic myeloproliferative disorders com-plicating pregnancy. Zhonghua Fu Chan Ke Za Zhi 2010; 45(12): 896−9.
Yazdani Brojeni P, Matok I, Garcia BF, Koren G. A systematic re-view of the fetal safety of interferon alpha. Reprod Toxicol 2012; 33(3): 265−8.
Melillo L, Tieghi A, Candoni A, Radaelli F, Ciancia R, Specchia G, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. Am J Heamtol 2009; 84(10): 636−40.
Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 2005; 129(3): 293−306.
Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay J, et al. Allogeneic haematopoietic stem cell transplantation for mye-lofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol 2011; 152(3): 331−9.
Messa RA. New drugs for the treatment of myelofrosis. Curr Hematol Malig Rep 2010; 5(1): 15−21.
Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program 2011; 2011: 222−30.
Hasselbalch HC. A new era for IFN-α in the treatment of Phila-delphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011; 4(6): 637−55.